140 related articles for article (PubMed ID: 37467030)
1. Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real-world evidence.
Cohen S; Bambace N; Ahmad I; Roy J; Tang X; Zhang MJ; Burns L; Barabé F; Bernard L; Delisle JS; Kiss T; Lachance S; Roy DC; Veilleux O; Sauvageau G
Blood Adv; 2023 Oct; 7(19):5717-5726. PubMed ID: 37467030
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
3. UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections.
Dumont-Lagacé M; Li Q; Tanguay M; Chagraoui J; Kientega T; Cardin GB; Brasey A; Trofimov A; Carli C; Ahmad I; Bambace NM; Bernard L; Kiss TL; Roy J; Roy DC; Lemieux S; Perreault C; Rodier F; Dufresne SF; Busque L; Lachance S; Sauvageau G; Cohen S; Delisle JS
Transplant Cell Ther; 2021 Jan; 27(1):76.e1-76.e9. PubMed ID: 33022376
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
5. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
6. UM171 Expansion of Cord Blood Improves Donor Availability and HLA Matching For All Patients, Including Minorities.
Dumont-Lagacé M; Feghaly A; Meunier MC; Finney M; Van't Hof W; Masson Frenet E; Sauvageau G; Cohen S
Transplant Cell Ther; 2022 Jul; 28(7):410.e1-410.e5. PubMed ID: 35311667
[TBL] [Abstract][Full Text] [Related]
7. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
8. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.
Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Allan D; Bredeson C; Sabloff M; Guru Murthy GS; Badar T; Hashmi S; Aljurf M; Litzow MR; Kebriaei P; Hourigan CS; Saber W
Transplant Cell Ther; 2023 Sep; 29(9):578.e1-578.e9. PubMed ID: 37406882
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
11. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation.
Konuma T; Kanda J; Uchida N; Nishijima A; Tanaka M; Ozawa Y; Sawa M; Onizuka M; Ota S; Maruyama Y; Kanda Y; Kawakita T; Ara T; Eto T; Nakamae H; Kimura T; Fukuda T; Atsuta Y;
Hematol Oncol; 2023 Feb; 41(1):147-158. PubMed ID: 36268564
[TBL] [Abstract][Full Text] [Related]
12. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
13. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A
Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725
[TBL] [Abstract][Full Text] [Related]
14. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
15. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation.
Gutman JA; Ross K; Smith C; Myint H; Lee CK; Salit R; Milano F; Delaney C; Gao D; Pollyea DA
Bone Marrow Transplant; 2016 Dec; 51(12):1588-1593. PubMed ID: 27400068
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
17. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
18. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
19. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
